This is a review about Smad3, based on 42 published articles (read how Labome selects the articles), using Smad3 antibody in all methods. It is aimed to help Labome visitors find the most suited Smad3 antibody.
Smad3 synonym: HSPC193; HsT17436; JV15-2; LDS1C; LDS3; MADH3; MAD homolog 3; MAD, mothers against decapentaplegic homolog 3; SMA- and MAD-related protein 3; SMAD, mothers against DPP homolog 3; hMAD-3; hSMAD3; mad homolog JV15-2; mad protein homolog; mad3; mothers against DPP homolog 3; mothers against decapentaplegic homolog 3

Cell Signaling TechnologyCell Signaling Technology Smad3 product
  • flow cytometryIn 2010, Ruth S Waterman et al. utilized Cell Signaling Technology Smad3 antibody to perform immunocytochemistry and flow cytometry in order to show that mesenchymal stem cell can be polarized by downstream TLR signaling into two distinctly acting phenotypes [ncbi , more ].
  • immunocytochemistryIn 2010, Ruth S Waterman et al. utilized Cell Signaling Technology Smad3 antibody to perform immunocytochemistry and flow cytometry in order to show that mesenchymal stem cell can be polarized by downstream TLR signaling into two distinctly acting phenotypes [ncbi , more ]. In 2008, Al Karim Khimji et al. used Cell Signaling Technology Smad3 antibody to ascertain whether the downstream signaling pathways mediated by TGF-beta vary in different liver injury models [ncbi , more ].
  • immunohistochemistryIn 2007, Lanying Song et al. utilized Cell Signaling Technology Smad3 antibody to study the role of Alk3 during AV cushion morphogenesis in mouse embryonic hearts [ncbi , more ].
  • western blotCell Signaling Technology Smad3 antibody was applied in 2009 to perform westn blot in order to investigate the relations between TGFbeta1 and TNFa [ncbi , more ], to demostrate that the target gene expression can be promoted through Smad2/3 activation [ncbi , more ]and to perform western blot in order to study the mechanism of the epithelial-mesenchymal transition in human mammary carcinoma cells induced by Six1 homeoprotein [ncbi , more ]. Cell Signaling Technology Smad3 antibody was used in 2008 to ascertain whether the downstream signaling pathways mediated by TGF-beta vary in different liver injury models [ncbi , more ], to perform western blot in order to show the mechanism that two functions of TGF become un-coupled during cancer development [ncbi , more ]and to carry out western blot analysis in order to investigate the roles for HMGA2 and Smads in the regulation of SNAIL1 expression during epithelial-mesenchymal transition [ncbi , more ]. In 2006, Kyung Song et al. utilized Cell Signaling Technology Smad3 antibody to study the role of epidermal growth factor in transforming growth factor beta signaling and growth suppression [ncbi , more ].
EMD MilliporeEMD Millipore Smad3 product
  • immunohistochemistryIn 2008, Miguel A Alejandre-Alcázar et al. used EMD Millipore Smad3 antibody to perform immunohistochemistry and western blot in order to study the dynamical regulation of TGF-beta signaling during late lung development in the human and mouse [ncbi , more ].
  • immunoprecipitationIn 2002, Lilly Y W Bourguignon et al. used EMD Millipore Smad3 antibody to study the effect of hyaluronan on the interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells [ncbi , more ].
  • western blotIn 2009, Lihua Ding et al. applied EMD Millipore Smad3 antibody to study the suppressing role of human FHL1 family members in the modulation of tumor cell growth through a TGF-beta like signaling pathway [ncbi , more ]. In 2008, Miguel A Alejandre-Alcázar et al. used EMD Millipore Smad3 antibody to perform immunohistochemistry and western blot in order to study the dynamical regulation of TGF-beta signaling during late lung development in the human and mouse [ncbi , more ]. In 2002, Lilly Y W Bourguignon et al. used EMD Millipore Smad3 antibody to study the effect of hyaluronan on the interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells [ncbi , more ].
Life Technologies CorporationLife Technologies Corporation Smad3 product
  • immunocytochemistryIn 2008, Al Karim Khimji et al. used Life Technologies Corporation Smad3 antibody to ascertain whether the downstream signaling pathways mediated by TGF-beta vary in different liver injury models [ncbi , more ].
  • immunohistochemistryIn 2009, Douglas S Micalizzi et al. employed Life Technologies Corporation Smad3 antibody to perform immunohistochemistry in order to study the mechanism of the epithelial-mesenchymal transition in human mammary carcinoma cells induced by Six1 homeoprotein [ncbi , more ].
  • immunoprecipitationIn 2002, Susan Fanayan et al. used Life Technologies Corporation Smad3 antibody to study a signaling pathway for IGFBP-3 from a cell surface receptor to nuclear transcriptional activity [ncbi , more ].
  • western blotIn 2009, Blanca Herrera et al. used Life Technologies Corporation Smad3 antibody to investigate the role of BMP9 signalling via ALK2/Smad1/Smad4 pathway in ovarian cancer [ncbi , more ]. Al Karim Khimji et al. used Life Technologies Corporation Smad3 antibody to ascertain whether the downstream signaling pathways mediated by TGF-beta vary in different liver injury models [ncbi , more ] in 2008 and Savita Bharathy et al. used Life Technologies Corporation Smad3 antibody to perform western blot [ncbi , more ]. In 2005, Taihao Quan et al. applied Life Technologies Corporation Smad3 antibody to study the role for AP-1 in the induction of Smad7 expression by UV irradiation in human skin fibroblasts [ncbi , more ]. In 2004, Michael B Major et al. applied Life Technologies Corporation Smad3 antibody to study the effect of gadd45beta3' enhancer on SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta [ncbi , more ]. In 2003, Pedro Soto et al. employed Life Technologies Corporation Smad3 antibody to demonstrate that SMAD2 and SMAD7 were involved in the post-translational regulation of Muc4 [ncbi , more ]. Jian Xu et al. utilized Life Technologies Corporation Smad3 antibody to evaluate the presence and function of the family of the TGFbeta signaling molecules Smads during follicle development [ncbi , more ] in 2002 and Susan Fanayan et al. used Life Technologies Corporation Smad3 antibody to study a signaling pathway for IGFBP-3 from a cell surface receptor to nuclear transcriptional activity [ncbi , more ].
R and D SystemsR and D Systems Smad3 product
  • western blotIn 2009, Matthew Thomas et al. utilized R and D Systems Smad3 antibody to investigate the role of ALK5 in the regulation of pulmonary arterial hypertension [ncbi , more ].
AbcamAbcam Smad3 product
  • western blotIn 2010, Shinako Araki et al. applied Abcam Smad3 antibody to investigate the role of TGFB1 in the regulation of Mdm2 expression and late-stage breast cancer metastasis [ncbi , more ].
Santa Cruz BiotechnologySanta Cruz Biotechnology Smad3 product
  • EMSAIn 2002, Christos Chadjichristos et al. applied Santa Cruz Biotechnology Smad3 antibody to study the effect of transforming growth factor- 1 (TGF- 1) on human type II collagen gene expression in articular chondrocytes and the relationship of it with Sp3/Sp1 ratio [ncbi , more ].
  • immunocytochemistryIn 2009, Joanna Boros et al. applied Santa Cruz Biotechnology Smad3 antibody to carry out immunofluorescence assays in order to investigate the role for transforming growth factor beta in regulating neuronal cell development [ncbi , more ]. In 2005, Constance E Runyan et al. used Santa Cruz Biotechnology Smad3 antibody to study the role of internalization in transforming growth factor beta 1-induced smad2 association with smad anchor for receptor activation (SARA) and smad2-dependent signaling in human mesangial cells [ncbi , more ].
  • immunohistochemistryIn 2005, Takayuki Furumatsu et al. used Santa Cruz Biotechnology Smad3 antibody to study chondrogenesis Induction by Smad3 [ncbi , more ]. In 2002, Chunming Dong et al. utilized Santa Cruz Biotechnology Smad3 antibody to demonstrate that alterations in the Smad pathway is responsible for TGF-beta hyperresponsiveness [ncbi , more ].
  • immunoprecipitationIn 2002, Ya Chung Tian et al. employed Santa Cruz Biotechnology Smad3 antibody to examine the influence of transforming growth factor (TGF) 1 on proximal tubular epithelial cell-cell interaction, with particular emphasis on the regulation of adherens junction complex formation [ncbi , more ]. In 2001, S L Stroschein et al. applied Santa Cruz Biotechnology Smad3 antibody to study SnoN ubiquitination and degradation [ncbi , more ].
  • western blotIn 2010, Shinako Araki et al. applied Santa Cruz Biotechnology Smad3 antibody to investigate the role of TGFB1 in the regulation of Mdm2 expression and late-stage breast cancer metastasis [ncbi , more ]. In 2009, Lihua Ding et al. applied Santa Cruz Biotechnology Smad3 antibody to study the suppressing role of human FHL1 family members in the modulation of tumor cell growth through a TGF-beta like signaling pathway [ncbi , more ]. Kyung Song et al. utilized Santa Cruz Biotechnology Smad3 antibody to study the role of epidermal growth factor in transforming growth factor beta signaling and growth suppression [ncbi , more ] in 2006 and Yasuko Yamamura et al. used Santa Cruz Biotechnology Smad3 antibody to detect Smad3 expression in COS7 cells [ncbi , more ]. In 2005, Che Chang Chang et al. utilized Santa Cruz Biotechnology Smad3 antibody to study transcriptional repression of smad4 [ncbi , more ]. Santa Cruz Biotechnology Smad3 antibody was employed in 2004 to study the pituitary prolactin expression and cell growth inhibited by activin [ncbi , more ], to study the impaired Smad7-Smurf mediated negative regulation of TGF- signaling in scleroderma fibroblasts [ncbi , more ]and to study apoptosis induceed through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells by activin receptor-like kinase-7 [ncbi , more ]. Kiyoshi Higashi et al. used Santa Cruz Biotechnology Smad3 antibody to study transforming growth factor-beta signaling [ncbi , more ] in 2003 and Dirk Haller et al. used Santa Cruz Biotechnology Smad3 antibody to study that transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation [ncbi , more ]. Santa Cruz Biotechnology Smad3 antibody was used in 2002 to study the role of Ets1 in the growth factor beta (TGF-beta) signaling pathway [ncbi , more ], to demonstrate that alterations in the Smad pathway is responsible for TGF-beta hyperresponsiveness [ncbi , more ]and to study the regulation of endoglin expression by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways [ncbi , more ]. In 2001, S L Stroschein et al. applied Santa Cruz Biotechnology Smad3 antibody to study SnoN ubiquitination and degradation [ncbi , more ].
Epitomics
  • immunocytochemistryIn 2008, Al Karim Khimji et al. used Epitomics Smad3 antibody to ascertain whether the downstream signaling pathways mediated by TGF-beta vary in different liver injury models [ncbi , more ].
  • immunohistochemistryIn 2009, Silvia Giampieri et al. utilized Epitomics Smad3 antibody to perform immunohistochemistry assays in order to study the important role of TGF-beta signalling in blood-borne metastasis [ncbi , more ].
  • western blotIn 2009, Chaoyang Jin et al. utilized Epitomics Smad3 antibody to carry out western blot analysis in order to investigate the role for Smurf2 in promoting breast cancer metastasis [ncbi , more ]. Sylvie Thuault et al. utilized Epitomics Smad3 antibody to carry out western blot analysis in order to investigate the roles for HMGA2 and Smads in the regulation of SNAIL1 expression during epithelial-mesenchymal transition [ncbi , more ] in 2008 and Al Karim Khimji et al. used Epitomics Smad3 antibody to ascertain whether the downstream signaling pathways mediated by TGF-beta vary in different liver injury models [ncbi , more ].
BD Biosciences
  • immunohistochemistryIn 2009, Akiyoshi Komuro et al. employed BD Biosciences Smad3 antibody to investigate the role of transforming growth factor Beta signaling in the regulation of tumor growth [ncbi , more ].
  • immunoprecipitationIn 2001, M Furuhashi et al. applied BD Biosciences Smad3 antibody to study Smad3 activation in the transforming growth factor beta signaling pathway [ncbi , more ].
  • western blotIn 2009, Blanca Herrera et al. used BD Biosciences Smad3 antibody to investigate the role of BMP9 signalling via ALK2/Smad1/Smad4 pathway in ovarian cancer [ncbi , more ]. In 2001, M Furuhashi et al. applied BD Biosciences Smad3 antibody to study Smad3 activation in the transforming growth factor beta signaling pathway [ncbi , more ].
TEN DIJKE
  • western blotIn 2003, Celine Prunier et al. used Smad3 antibody to study the role of TGF- signaling in the phosphorylation of Smad2 and Smad3 [ncbi , more ].
Source BioScience
  • western blotIn 2005, Xiao Liang Zhang et al. applied Source BioScience Smad3 antibody to study TGF-beta1 signaling [ncbi , more ].
Articles Reviewed
  1. Ruth S Waterman et al. (2010). "A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype".PMID 20436665
  2. Blanca Herrera et al. (2009). "Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation".PMID 19996292
  3. Shinako Araki et al. (2010). "TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer".PMID 19955655
  4. Silvia Giampieri et al. (2009). "Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility".PMID 19838175
  5. Joanna Boros et al. (2009). "Overlapping promoter targeting by Elk-1 and other divergent ETS-domain transcription factor family members".PMID 19789270
  6. Douglas S Micalizzi et al. (2009). "The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling".PMID 19726885
  7. Akiyoshi Komuro et al. (2009). "Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling".PMID 19351925
  8. Xiaoying Liu et al. (2009). "Transforming growth factor beta1-mediated activation of the smooth muscle alpha-actin gene in human pulmonary myofibroblasts is inhibited by tumor necrosis factor-alpha via mitogen-activated protein kinase kinase 1-dependent induction of the Egr-1 transcr".PMID 19261809
  9. Marcela Guzman-Ayala et al. (2009). "Graded Smad2/3 activation is converted directly into levels of target gene expression in embryonic stem cells".PMID 19172185
  10. Chaoyang Jin et al. (2009). "Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness".PMID 19155312
  11. Lihua Ding et al. (2009). "Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway".PMID 19139564
  12. Matthew Thomas et al. (2009). "Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrot".PMID 19116361
  13. Sylvie Thuault et al. (2008). "HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition".PMID 18832382
  14. Al Karim Khimji et al. (2008). "Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation".PMID 18753413
  15. Savita Bharathy et al. (2008). "Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype".PMID 18339844
  16. Miguel A Alejandre-Alcázar et al. (2008). "TGF-beta signaling is dynamically regulated during the alveolarization of rodent and human lungs".PMID 18095342
  17. Lanying Song et al. (2007). "Essential functions of Alk3 during AV cushion morphogenesis in mouse embryonic hearts".PMID 16959237
  18. Kyung Song et al. (2006). "Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II".PMID 16428382
  19. Yasuko Yamamura et al. (2006). "RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells".PMID 16373335
  20. Xiao Liang Zhang et al. (2005). "Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling".PMID 15661740
  21. Che Chang Chang et al. (2005). "Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4".PMID 15637079
  22. Takayuki Furumatsu et al. (2005). "Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment".PMID 15623506
  23. Constance E Runyan et al. (2005). "The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells".PMID 15613484
  24. Taihao Quan et al. (2005). "Ultraviolet irradiation induces Smad7 via induction of transcription factor AP-1 in human skin fibroblasts".PMID 15579469
  25. Byung Chul Kim et al. (2004). "Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells".PMID 15107418
  26. Annie Lacerte et al. (2004). "Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin".PMID 15031321
  27. Yoshihide Asano et al. (2004). "Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts".PMID 14722617
  28. Michael B Major et al. (2004). "Identification of a gadd45beta 3' enhancer that mediates SMAD3- and SMAD4-dependent transcriptional induction by transforming growth factor beta".PMID 14630914
  29. Kiyoshi Higashi et al. (2003). "Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3".PMID 12917425
  30. Celine Prunier et al. (2003). "The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation".PMID 12732634
  31. Dirk Haller et al. (2003). "Transforming growth factor-beta 1 inhibits non-pathogenic Gram negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation".PMID 12672795
  32. Pedro Soto et al. (2003). "SMAD2 and SMAD7 involvement in the post-translational regulation of Muc4 via the transforming growth factor-beta and interferon-gamma pathways in rat mammary epithelial cells".PMID 12668667
  33. Tilman Sanchez-Elsner et al. (2002). "Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways".PMID 12228247
  34. Christos Chadjichristos et al. (2002). "Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio".PMID 12186868
  35. Lilly Y W Bourguignon et al. (2002). "Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells".PMID 12145287
  36. Jian Xu et al. (2002). "Stage-specific expression of Smad2 and Smad3 during folliculogenesis".PMID 12021033
  37. Ya Chung Tian et al. (2002). "Interaction between the transforming growth factor-beta type II receptor/Smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly".PMID 12000714
  38. Joanna Czuwara-Ladykowska et al. (2002). "Ets1 is an effector of the transforming growth factor beta (TGF-beta ) signaling pathway and an antagonist of the profibrotic effects of TGF-beta".PMID 11919190
  39. Chunming Dong et al. (2002). "Deficient Smad7 expression: a putative molecular defect in scleroderma".PMID 11904440
  40. Susan Fanayan et al. (2002). "Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling".PMID 11751851
  41. S L Stroschein et al. (2001). "Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN".PMID 11691834
  42. M Furuhashi et al. (2001). "Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway".PMID 11438668